More than half of patients with a rheumatic disease or immunologic condition undergoing methotrexate treatment reside in states in which the overturning of Roe v. Wade can jeopardize access to medications with abortifacient potential

Starzyk, K., Hoffman, V., Su, Z., Meng, R., Bhartia, M., Curhan, G., Yoshida, K., & Paulus, J. K. (2023). More than half of patients with a rheumatic disease or immunologic condition undergoing methotrexate treatment reside in states in which the overturning of Roe v. Wade can jeopardize access to medications with abortifacient potential. Arthritis and Rheumatology, 75(2), 328-329. https://doi.org/10.1002/art.42398